On October 13, 2026, Zhejiang Shengyao Guangyan Pharmaceutical Co., Ltd. (hereinafter referred to as "Shengyao Guangyan"), a wholly-owned subsidiary of Asia Pacific Pharmaceutical (002370.SZ), signed a "Letter of Intent for Cooperation on Innovative Drug Technology Transaction" with Quzhou Fuda Biomedical Innovation Research Institute (hereinafter referred to as "Quzhou Fudan Research Institute"), intending to introduce all the technological achievements of the Class 1.1 small molecule innovative drug "a BODIPY photosensitizer for acne treatment" held by Quzhou Fudan Research Institute .
The target project of this collaboration is a Class 1.1 small molecule innovative drug, "A BODIPY-type photosensitizer for acne treatment," belonging to the cutting-edge field of photodynamic therapy. It is currently in the PCC (preclinical candidate compound) stage, with one Chinese patent application filed. The indication is acne and other applications. The transaction consideration includes a total of RMB 25 million for R&D and approval milestone payments, a total commercialization milestone payment not exceeding RMB 40 million, and subsequent product sales revenue sharing (calculated at 2.00% of the product's annual net sales over ten years, with a maximum cumulative amount not exceeding RMB 100 million ).

Source: https://mp.weixin.qq.com/s?__biz=MzA5Njc0MTAxOQ==&mid=2650033491&idx=2&sn=0acfe69713aae899421bc4c8d33101c2&chksm=89939f3bf89bb9f002129378fbe4bfc53f860